Premenopausal Early Breast Cancer: Medical Management

1
Premenopausal Early Breast Cancer Medical
Management

• Dr Prue Francis
• Head Breast Medical Oncology
• Peter MacCallum Cancer Centre

2
Pathology Information Required for Optimal
Systemic Therapy Decisions

• Size tumour (invasive component)
• Grade tumour
• Presence of lymphovascular invasion (LVI)
• Lymph node involvement (no. of positive nodes)
• NB negative sentinel node maybe false negative

3
Pathology Information Required for Optimal
Systemic Therapy Decisions

• ER cells positive and intensity of staining
• PR cells positive and intensity of staining
• ER/PR results on Core Biopsy maybe more
  accurate. RMH study 9 tumours assessed as
  receptor negative on surgical sample had positive
  hormone receptors when assessed on core biopsy.

4
Pathology Information Required for Optimal
Systemic Therapy Decisions

• HER2 testing best done on surgical sample
  (unless large tumour for neoadjuvant Rx )
• Also ask for CISH testing (HER2 testing by IHC
  6 IHC 1 are HER2 amplified while only 80 of
  IHC 3 are amplified)

5
Premenopausal Early Breast CancerAdjuvant
Systemic Therapy Decisions

• (1) Chemotherapy
• (2) Hormonal Therapy (for ER or PR positive)
• (3) Biologic Therapy (for HER2 positive)

6
Premenopausal Early Breast Cancer Adjuvant
Systemic Therapy Decisions

• Have a low threshold for offering some
• form of adjuvant systemic therapy

7
Tumour Size and Recurrence-Free Survival in Node
Negative Breast Cancer With No Adjuvant Treatment
8
Premenopausal Early Breast Cancer Adjuvant
Systemic Therapy Decisions

• Adjuvantonline.com (available on internet)
• Enter data on patients age, health, tumor size
  and grade, ER status, lymph node spread
• Gives 10 year prediction of risk of recurrence
  and death according to systemic treatments
  chosen
• (i) none
• (ii) hormone (eg tamoxifen, AI, tamoxifen?AI)
• (iii) chemotherapy (of various intensities)
• (iv) chemotherapy hormone

9
Premenopausal Early Breast CancerAdjuvant
Systemic Therapy Decisions

• Adjuvantonline.com imperfect tool
• Cant enter how strongly positive the ER is
• Doesnt include the PR status
• Still developing model with HER2 status/Rx
• Cant enter exact tumour size and nodal status
  only a range ( ie. 1-3 nodes)

10
Premenopausal Early Breast CancerAdjuvant
Systemic Therapy Decisions Whats New?

• Oncotype DX Assay
• Suitable for node negative ER/PR positive tumors
• Commercial assay based on 21 genes (not funded)
• Patient has to pay 3000 - Send tumour sample
  to USA
• Recurrence Score (RS) correlates with a
  numerical risk of distant metastases at 10 yrs if
  treated with tamoxifen if low RS may avoid
  chemotherapy. High RS should get chemotherapy

11
Oncotype DX
Multi-gene RT-PCR Assay for Predicting Recurrence
in Node Negative Breast Cancer Patients - NSABP
B-14 Study.
Results
Recurrence Score as a Continuous Predictor
Low RS lt 18 Rec. Rate 6.8 C.I. 4.0 - 9.6
Intermediate RS 18 - 31 Rec. Rate 14.3 C.I.
8.3 - 20.3
High RS ? 31 Rec. Rate 30.5 C.I. 23.6 -
37.4
Paik .S. et al. 26th annual San Antonio breast
cancer symposium 2004.
12
Premenopausal Early Breast CancerAdjuvant
Systemic Therapy Decisions

• Chemotherapy
• consider in all Hormone Receptor negative tumours
• (ie. ER ve and PR ve)
• consider in all HER2 Positive tumours
• consider in all Node Positive tumours
• Benefit when added (prior to) tamoxifen in
  hormone receptor positive tumours

13
Premenopausal Early Breast CancerAdjuvant
Chemotherapy

• Adjuvantonline describes 1st, 2nd and 3rd
  generation regimens
• Higher generations more toxic but more effective
  (used in patients at higher risk for relapse)
• 1st generation AC x 4 or CMF x 6
• 2nd generation FEC 100 x 6 or TC x 4 etc
• 3rd generation FEC x 3 ? T x 3 etc

14
Adjuvant Chemotherapy vs None in Women lt 50 yrs

• Absolute Difference in Relapse Rates
• (at 15 years)
• Node Negative Breast Cancer 10
• Node Positive Breast Cancer 13

15
Premenopausal Early Breast CancerAdjuvant
Chemotherapy- Late Toxicities

• Premature menopause
• Cardiac toxicity (with anthracyclines, herceptin)
• Leukemia (AC or FEC but not CMF)
• Peripheral Neuropathy (paclitaxel gt docetaxel)

16
Premenopausal Early Breast CancerAdjuvant
Hormonal Therapy

• Tamoxifen standard therapy for all ER or PR ve
• Benefit when added to chemotherapy
• Five years tamoxifen better than 2 years.
• ? 10 years better than 5 years in premenopausal
  women await publication of ATLAS trial
• Women (especially those not tolerating well) need
  to know that it makes a big difference

17
(No Transcript)
18
(No Transcript)
19
Premenopausal Early Breast CancerAdjuvant
Hormonal Therapy

• Tamoxifen
• Previously used as a fertility treatment
• Women may not menstruate but be fertile
• Can harm a developing fetus
• Need to discuss the need for non-hormonal
  contraception
• Cease pre/post-operatively re risk thrombosis

20
Premenopausal Early Breast CancerAdjuvant
Hormonal Therapy

• Aromatase Inhibitors (AI)
• Anastrozole, letrozole, exemestane
• Effectiveness in women lt 45 years who seem
  postmenopausal after chemotherapy is uncertain
  (unless ovaries removed). BEWARE..
• AI GnRH injections (to suppress ovaries) being
  tested in trials eg SOFT and TEXT

21
Premenopausal Early Breast CancerAdjuvant
Hormonal Therapy

• GnRH Analogues (eg goserelin zoladex, and
  triptorelin)
• Given by injection every 4 weeks
• Reversible form of ovarian function suppression
  (makes patient temporarily postmenopausal)
• TGA approved but not PBS reimbursed
• Sometimes used as alternative to chemotherapy
• Benefit after chemotherapy unknown (SOFT)

22
Premenopausal Hormone Receptor Positive Breast
Cancer Adjuvant Therapy

• Chemotherapy effective
• Tamoxifen effective
• Ovarian ablation effective
• Women lt 35 years worse outcomes if ER /PR ve
• Important Questions Remain
• Are all three treatments required in very young
  women?
• Are aromatase inhibitors superior to tamoxifen in
  premenopausal women if suppress ovarian function?

23
SOFT (Suppression of Ovarian Function
Trial) IBCSG 24-02 Premenopausal Trial
Stratification
Treatments
Tamoxifen for 5 years
R A N D O M I S A T I O N
Institution Prior chemotherapy (no/yes) Number
of positive lymph nodes (0 1) Intended method
of OFS (GnRH analogue for 5 yrs oophorectomy
ovarian irradiation)
SURGERY
OFS plus Tamoxifen for 5 years
OFS plus Exemestane for 5 years
24
Premenopausal Early Breast CancerAdjuvant
Hormonal Therapy

• Ovarian ablation (surgical oophorectomy) is an
  effective treatment for hormone receptor positive
  tumours
• Oophorectomy/ Ovarian suppression tamoxifen
  sometimes used instead of chemotherapy in node
  negative low risk tumours with strong ER PR
• Salpingo-oophorectomy maybe chosen in BRCA gene
  carriers for reducing risk of current ER ve
  breast cancer, future new breast and future
  ovarian cancer

25
Premenopausal Early Breast CancerBiologic
Therapy

• Trastuzumab (Herceptin)
• For HER2 positive tumours give concurrently
  with taxane chemotherapy and continue for 12
  months with heart monitoring every 3 months
• Regimens
• AC ?taxane herceptin (takes 15 mths)
• TCH x 6 docetaxel carboplatin herceptin
• (takes 12 mths)
• ? Need infusaport if 2nd surgery required

26
Disease-Free Survival
AC?TH
87
85
AC?T
75

67
N Events AC?T 1679 261 AC?TH 1672 134
HR0.48, 2P3x10-12
Years From Randomization
B31/N9831
27
B-31/N9831 Survival
AC?TH
94
91
AC?T
92
87
N Deaths AC?T 1679 92 AC?TH 1672 62
HR0.67, 2P0.015
Years From Randomization
B31/N9831
28
Premenopausal Early Breast CancerBiologic
Therapy

• Current Adjuvant Trials for HER2 ve pts
• ALTTO comparing herceptin, lapatinib or
  combination in pts getting chemotherapy
• BETH comparing herceptin/- bevacizumab
  (avastin) in pts getting chemotherapy

29
Premenopausal Early Breast CancerBiologic Therapy

• Bevacizumab (avastin)
• Currently being tested in adjuvant trials
• BETH trial (in HER2 positive tumours)
• BEATRICE (in triple negative tumours ie. ER
  negative, PR negative, HER2 negative)

30
Premenopausal Early Breast CancerFertility
Considerations

• Chemotherapy may cause menopause or reduced
  ovarian reserve
• Delaying pregnancy for 5 years of hormonal
  therapy will reduce fertility
• Fertility after breast cancer treatment is age
  and regimen dependent

31
Risk of Menopause During the First Year After
Breast Cancer Diagnosis CMF or CEF
Goodwin et al JCO 172365, 1999
32
Risk of Menopause varies with type of
chemotherapy

• classic CMF (6 months) --gt 69 become menopausal
• AC x 4 (3 months) --gt 34 become menopausal

33
STRATEGIES TO PRESERVE FERTILITY

• ovarian protection during chemo
• gamete, tissue and embryo storage pre chemo
• use of donor oocytes if necessary

34
CRYOPRESERVATION

• mature oocytes
• embryos
• ovarian tissue

35
AUTOGRAFTINGThe Lancet Oct 2004

• Livebirth after orthotopic transplantation of
  cryopreserved ovarian tissue
• J Donnez, M M Dolmans, D Demylle, P Jadoul, C
  Pirard, J Squifflet, B Martinez-Madrid, A Van
  Langendonckt
• Lancet 2004 364 1405-10

36
SWOG 0230/ IBCSG 34 POEMS Phase III Trial of
Zoladex During Chemotherapy to Reduce Ovarian
Failure After Standard Adjuvant Chemotherapy in
Hormone Receptor Negative Breast Cancer
37
STUDY SCHEMA

STRATIFY
Zoladex standard chemo

• lt50 yo
• premenopausal
• Stage I, II, IIIA
• HR negative
• Adjuvant cyclophosphamide containing chemo
  planned

• age
• lt40 vs gt40
• chemo type

RANDOMISE
Standard chemo alone
38
POEMS (IBCSG 34) Trial Rationale

• No disease advantage to premature ovarian failure
  in this hormone receptor negative subgroup
• Disadvantages hot flushes, genitourinary/sexual
  dysfunction, mood changes, accelerated
  osteoporosis, infertility

39
POEMS (IBCSG 34) Trial Rationale

• Suppression of the pituitary-gonadal axis may
  help to preserve ovarian follicles and germinal
  epithelium from toxic effects of chemotherapy
• Several small Phase II studies have examined the
  role of GnRH agonists (eg Zoladex) as gonadal
  chemoprotectants
• (Blumenfeld 1999, Damewood 1986, Waxman 1987,
  Recchia 2002)

40
Pregnancy After Early Breast Cancer

• No evidence that it increases risk of recurrence
• Potential problem if relapse during pregnancy of
  how to treat
• If cancer does relapse later, child will likely
  experience death of mother at young age
• Relapses can occur between 5-10 years (especially
  in hormone receptor positive tumours)

41
Early Breast Cancer

• The Good News
• Majority cured with optimal therapy

42
The statistics are compelling
Breast Cancer Deaths
43
Positive Proof of Progress in Early Breast Cancer

• Progressive reduction in surgery needed
• Progressive reduction in risk of relapse